The Lankenau Institute for Medical Research
Monoclonal antibodies now comprise a major group of medicines, encompassing a multi-billion dollar market with diverse uses in research, diagnosis, prognosis, and therapy. At present, such antibodies are generated from rodents and must be “humanized” for therapeutic use. Pure human antibodies are expected to offer many clinical benefits but methods to generate them have been elusive.
The Center for Human Antibody Technology (CHAT) is a core facility that uses a new and powerful human antibody cloning platform technology developed by LIMR Associate Professor, Scott Dessain, M.D., Ph.D. The CHAT will use this platform along with a state-of-the-art, high throughput antibody production and screening facility to produce human antibodies for use in the treatment of infectious disease, cancer, and neurological illnesses. The CHAT is available as a regional resource to provide academic investigators with the opportunity to create their own human antibody therapeutics.
Scott Dessain, MD, PhD
Center for Human